$KIDS

Quoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.

Squadron Capital LLC sold 336,831 shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01. Filed jointly with Squadron Capital Holdings LLC (10% owner).

Pritzker Jennifer N. sold 336,831 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01.

Pelizzon David R sold 336,831 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01.

Pritzker Jennifer N. sold 38,300 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26.

Squadron Capital LLC sold 38,300 shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with Squadron Capital Holdings LLC (10% owner).

Pelizzon David R sold 38,300 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26.

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-Year WARSAW, Ind., August 4, 2026 -- OrthoPediatrics Corp

Simply Wall St said it reassessed OrthoPediatrics’ valuation assumptions, raising its fair value estimate from $24.00 to about $24.67 per share. It lowered long-term revenue growth to ~11.85% (from ~12.25%) and net profit margin to ~12.19% (from ~13.33%). The model’s future P/E increased to ~20.2x (from ~18.4x) and the discount rate fell to ~8.01% (from ~8.18%).